Renan Ozyerli, MD, MSD Turkey
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
ImuneksFarma currently has three healthcare segments; OTC, Pharma (RX), and R&D.
Imuneks’ OTC portfolio is concentrated in the immunology, Ear Nose and Throat, Gastroenterology, Orthopedics and PT areas. These products all have unique benefits to the patients, and are either developed by Imuneks, or by partners with best in class products.
In the RX area, Imuneks has developed three supergeneric products which are already approved in the EU and US markets. These products have improved ease of use, increased efficiency and diminished side effects.
The Imuneks R&D team is working with more than five original pharmaceutiaal treatments and five unique OTC products that are in the pipeline. With two internationally approved patents and a portfolio of new patent applications in different indications, Imuneks Farma is always looking for new and improved ways to treat and cure.
Prof. Dr. Bülent Tarcan Cad.Pak İş Merkezi No:5 Gayrettepe / İstanbul
Contact us at http://www.imuneksfarma.com/
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
Raphaël Esposito, director of the French Chamber of Commerce in Turkey, sheds light on issues ranging from venture partnerships to cultural specificities, while underlining Turkey’s capacity to respond to the…
Asli Özelli, newly appointed executive director of AmCham Turkey, discusses the economic landscape of Turkey and its attractiveness for American companies, in addition to highlighting her priorities in her new…
Hande Demirdere, general manager of Pierre Fabre Pharma in Turkey, sheds light on the affiliate’s impressive 93 percent growth in 2017 while highlighting where to target development opportunities in the…
Selim Giray, the recently appointed VP and general manager of GSK Turkey, provides insights into the company’s eye-catching footprint and commitment to Turkey, his ambition to integrate into the market’s…
In Summer 2018, we spoke to Adriano Antonio Treve, then general manager of Roche Turkey, now Area Head Central Eastern Europe, Turkey, Russia, Central Asia, Iran, Pakistan & Indian Subcontinent.…
Elif Aral, country manager of Pfizer Turkey, stresses that Turkey will continue to be perceived as essential and important, where healthcare is a top priority with its young but aging…
Mustafa Kemal Erol , president of the Turkish Society of Cardiology, introduces one of the oldest and largest societies in the country divulges their best collaborations with the Ministry of…
Abdi İbrahim Otsuka, the Turkish-Japanese hybrid pharmaceutical company, celebrated their five-year anniversary just last year and have ambitions to become the Number One Japanese company in Turkey. Elif Elkin, in…
Mark Dekker, general manager of Astellas in Turkey, describes the ever-increasing commitment of the company to Turkey and the recent doubling of Astellas’ portfolio in the country, while pinpointing the…
Mahmut Gümüş, president of the Turkish Society of Medical Oncology, paints a descriptive picture of the oncology situation in the country, with the looming epidemiological shift set to transform the…
Hakan Koçak, CEO–general manager of Koçak Farma, a company with 47 years in the pharmaceutical industry and the biggest production facility in Turkey, gives a thorough insight into Koçak Farma’s…
See our Cookie Privacy Policy Here